Apoptosis in immune-mediated liver diseases

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 144-149

  Kahraman, Alisan ^a   Gerken, Guido ^a   Canbay, Ali ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Apoptosis; Autoimmunity; Cholestasis; Stress induced ligands

Indexed keywords

FAS LIGAND; HLA A ANTIGEN; HLA B ANTIGEN; IMMUNOGLOBULIN A; URSODEOXYCHOLIC ACID;

APOPTOSIS; AUTOIMMUNE HEPATITIS; CELL DEATH; CELL STRESS; CELLULAR IMMUNITY; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; LIVER NECROSIS; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

APOPTOSIS; AUTOIMMUNE DISEASES; BILE DUCTS; CHOLANGITIS, SCLEROSING; FATTY LIVER; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; MAJOR HISTOCOMPATIBILITY COMPLEX;

EID: 77952565969     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000299799     Document Type: Review

References (32)

1. Canbay A, Friedman S, Gores GJ: Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004;39:273-278.
2. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B: Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006;130:435-452.
3. Lapierre P, Beland K, Alvarez F: Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007;149:107-113.
4. Bai J, Odin JA: Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev 2003;2:36-42.
5. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N: Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2009, E-pub ahead of print.
6. Holdenrieder S, Eichhorn P, Beuers U, et al: Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res 2007;27:2041-2045.
7. Tripathi D, Neuberger J: Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009;29:286-296.
8. Tsikrikoni A, Kyriakou DS, Rigopoulou EI, Alexandrakis MG, Zachou K, Passam F, Dalekos GN: Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 2005;42:393-399.
9. Seki S, Kitada T, Iwai S, et al: Immunohistochemical detection of Fas and apoptosis in type-1 autoimmune hepatitis. Hepatogastroenterology 2003;50:1274-1277.
10. Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM: Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001;21:272-279.
11. Derkow K, Loddenkemper C, Mintern J, et al: Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology 2007;46:1155-1165.
12. Marzioni M, Glaser SS, Alpini G, LeSage GD: Role of apoptosis in development of primary biliar y cirrhosis. Dig Liver Dis 2001;33:531-533.
13. Tinmouth J, Lee M, Wanless IR, Tsui FW, Inman R, Heathcote EJ: Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 2002;22:228-234.
14. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A: Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001;108:223-232.
15. Iwata M, Harada K, Kono N, Kaneko S, Kobayashi K, Nakanuma Y: Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis. Hum Pathol 2000;31:179-184.
16. Yokomori H, Oda M, Yoshimura K, et al: Expression of intercellular adhesion mole-cule-1 and lymphocyte function-associated antigen-1 protein and messenger RNA in primary biliary cirrhosis. Intern Med 2003;42:947-954.
17. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D: HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
18. Fukushima N, Nalbandian G, Van De Water J, et al: Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC. Hepatology 2002;36:1383-1392.
19. Matsumura S, Van De Water J, Leung P, et al: Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 2004;39:1415-1422.
20. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ: Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002;123:1323-1330.
21. Ijare OB, Bezabeh T, Albiin N, Arnelo U, Bergquist A, Lindberg B, Smith IC: Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an indication of cholestasis: a 1H MRS study. NMR Biomed 2009;22:471-479.
22. Pares A, Caballeria L, Rodes J, et al: Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000;32:561-566.
23. Amaral JD, Castro RE, Sola S, Steer CJ, Rodrigues CM: p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J Biol Chem 2007;282:34250-34259.
24. Neuman MG, Cameron RG, Haber JA, Katz GG, Blendis LM: An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis. Liver 2002;22:235-244.
25. Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R: Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin Exp Med 2008;8:1-7.
26. Roberts LR, Kurosawa H, Bronk SF, et al: Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology 1997;113:1714-1726.
27. Ong JP, Younossi ZM: Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16, vii.
28. Farrell GC, Larter CZ, Hou JY, et al: Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 2009;24:443-452.
29. Kohga K, Takehara T, Tatsumi T, et al: Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 2008;99:1643-1649.
30. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005;43:1013-1020.
31. Jinushi M, Takehara T, Tatsumi T, et al: Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003;104:354-361.
32. Kahraman A, Schlattjan M, Kocabayoglu P, et al: Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 2010;51:92-102.